Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 2/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22379757 | 1.00 | NR3C1 (0.35) | NR3C1ESR2PTGER4TDP2KDM1A | |
| SCHEMBL22378267 | 0.98 | NR3C1 (0.36) | NR3C1ESR2PTGER4TDP2KDM1A | |
| SCHEMBL22378272 | 0.98 | NR3C1 (0.36) | NR3C1ESR2PTGER4TDP2KDM1A | |
| SCHEMBL24831026 | 0.95 | NR3C1 (0.34) | NR3C1ALDH1A1LMNAHPGDMAPK1 | |
| SCHEMBL22377882 | 0.95 | NR3C1 (0.36) | NR3C1ESR2PTGER4TDP2TNKS2 | |
| SCHEMBL22379590 | 0.95 | NR3C1 (0.36) | NR3C1ESR2PTGER4TDP2TNKS2 | |
| SCHEMBL22378767 | 0.93 | NR3C1 (0.37) | NR3C1ESR2PTGER4TDP2KDM1A | |
| SCHEMBL22377611 | 0.93 | NR3C1 (0.34) | NR3C1ESR2PTGER4KDM1ATNKS2 | |
| SCHEMBL22379753 | 0.93 | NR3C1 (0.34) | NR3C1ESR2PTGER4KDM1ATNKS2 | |
| SCHEMBL22378760 | 0.93 | NR3C1 (0.34) | NR3C1ESR2PTGER4KDM1ATNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800797-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-10-24 | — | — | US | disclosed |
| US-20200274074-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200274074-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CYP1A1, CRY2 | NR3C1 1012/4885ESR2 473/4885PTGER4 1068/4885 |
| US-11800797-B2 | Heterocyclic compound and organic light-emitting device including the same | CRY1, CYP1A1, CRY2 | NR3C1 1012/4885ESR2 473/4885PTGER4 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.